{"result": "(\"entity\"<|>CALCITRIOL<|>ORGANIZATION<|>Calcitriol is a metabolite of vitamin D used to treat conditions related to calcium metabolism, particularly in patients with low vitamin D levels.)\n##\n(\"entity\"<|>ERGOCALCIFEROL<|>ORGANIZATION<|>Ergocalciferol, also known as vitamin D2, is a form of vitamin D used to treat vitamin D deficiency.)\n##\n(\"entity\"<|>COLECALCIFEROL<|>ORGANIZATION<|>Colecalciferol, also known as vitamin D3, is a form of vitamin D that is effective in treating vitamin D deficiency.)\n##\n(\"entity\"<|>HYPERCALCEMIA<|>EVENT<|>Hypercalcemia is a condition characterized by elevated calcium levels in the blood, often associated with vitamin D treatment.)\n##\n(\"entity\"<|>HIPOCALCEMIA<|>EVENT<|>Hypocalcemia is a condition characterized by low calcium levels in the blood, which can be caused by vitamin D deficiency.)\n##\n(\"entity\"<|>VITAMIN D<|>ORGANIZATION<|>Vitamin D is a fat-soluble vitamin that is important for maintaining calcium and phosphate balance in the body.)\n##\n(\"entity\"<|>ANTIEPILEPTIC MEDICATION<|>ORGANIZATION<|>Antiepileptic medications are drugs used to treat epilepsy, which can affect vitamin D metabolism.)\n##\n(\"relationship\"<|>CALCITRIOL<|>ERGOCALCIFEROL<|>Calcitriol is a metabolite derived from ergocalciferol, used in the treatment of vitamin D deficiency<|>6)\n##\n(\"relationship\"<|>CALCITRIOL<|>COLECALCIFEROL<|>Calcitriol is a metabolite derived from colecalciferol, used in the treatment of vitamin D deficiency<|>6)\n##\n(\"relationship\"<|>HYPERCALCEMIA<|>VITAMIN D<|>Hypercalcemia can occur as a side effect of vitamin D treatment<|>7)\n##\n(\"relationship\"<|>HIPOCALCEMIA<|>VITAMIN D<|>Hypocalcemia can be treated with vitamin D supplementation<|>8)\n##\n(\"relationship\"<|>ANTIEPILEPTIC MEDICATION<|>VITAMIN D<|>Antiepileptic medications can increase the metabolism of vitamin D, affecting its levels in the body<|>5)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: ol inclu-\n         D.  Todas las respuestas anteriores son correctas.                                                                                     yen un rápido inicio de acción (horas) y una vida media biológica de aproximadamente 4\n                                                                                                                                                a 6 horas. Si bien la hipercalcemia es más común durante el tratamiento con calcitriol que\n                                                                                                                                                con vitamina D, el cese del tratamiento es seguido por la resolución de la hipercalcemia en\n         COMENTARIO                                                                                                                             unos pocos días en lugar de unas pocas semanas.\n         La ausencia de radiación solar y el consumo deficiente o la alteración de la absorción de                                              Cuando la deficiencia de vitamina D es la causa de la hipocalcemia, la administración de\n         vitamina D pueden provocar una carencia de vitamina D porque las dos fuentes de vitamina                                               calcio solo es transitoriamente efectiva. La hipocalcemia debido a la deficiencia de vitami-\n         D son los alimentos y la síntesis cutánea después de la exposición a la radiación ultravioleta.                                        na D generalmente se trata con ergocalciferol (vitamina D) o colecalciferol (vitamina D3).2\n         La malabsorción es una causa importante de carencia de vitamina D en todos los grupos                                                  En el contexto de una deficiencia no complicada de vitamina D, la vitamina D2 o D3 corrige\n         de edad. La absorción de la vitamina D depende de su emulsificación por los ácidos biliares,                                           la deficiencia.\n         porque es una vitamina liposoluble. Cualquier causa de malabsorción o el síndrome del                                                  Los metabolitos de la vitamina D (calcitriol, dihidrotaquisterol, calcidiol) se pueden usar\n         intestino corto pueden causar una carencia de vitamina D; por tanto, en pacientes con una                                              para tratar la hipocalcemia, particularmente cuando hay un metabolismo anormal de la\n         concentración muy baja de 25(OH)D (menor de 8 ng/dl) hay que descartar una malabsor-                                                   vitamina D (enfermedad renal o hepática). La principal ventaja de la vitamina D sobre los\n         ción grasa.                                                                                                                            metabolitos de la vitamina D es su bajo coste. Las desventajas incluyen la necesidad de\n         La 25(OH)D y la 1,25(OH)2D3              se segregan con las sales biliares y pasan a la circulación                                   metabolismo hepático y renal y de inicio lento y larga duración de acción.\n         enterohepática. En pacientes con medicación antiepiléptica o para la tuberculosis puede                                                El calcidiol no requiere 25-hidroxilación hepática y, por lo tanto, es más útil en pacientes\n         aumentar el metabolismo de la vitamina D y bajar la concentración sanguínea de 25(OH)D.                                                con enfermedad hepática. Su acción es más rápida y no tan prolongada como la de la\n         El fenobarbital, la primidona, la fenitoína, la rifampicina y la glutetimida aceleran la inacti-                                       vitamina D, pero más lenta de inicio y más prolongada que la del calcitriol.\n         vación hepática de la vitamina D.                                                                                                      Referencias:\n         Referencias:                                                                                                                           •  Dawson-Hughes B. Vitamin D deficiency in adults: Definition, clinical manifestations and treatment. Rosen CJ, ed. UptoDate.\n         • Dawson-Hughes B. Vitamin D deficiency in adults: Definition, clinical manifestations and treatment. Rosen CJ, ed. UptoDate.             Waltham, MA: UpToDate Inc. https://www.uptodate.com (acceso 10 de junio de 2019)\n           Waltham, MA: UpToDate Inc. https://www.uptodate.com (acceso 10 de junio de 2019).                                                    •  Melmed S, Polonsky KS, Reed Larsen P, Kronenberg HM. Williams Textbook of Endocrinology. 13.ª ed. Philadelphia: Elsevier; 2016.\n         • Drezner MK. Causes of vitamin D deficiency and resistance. Rosen CJ, ed. UptoDate. Waltham, MA: UpToDate Inc. https://www.\n           uptodate.com (acceso 10 de junio de 2019).\n         • Melmed S, Polonsky KS, Reed Larsen P, Kronenberg HM. Williams Textbook of Endocrinology. 13.ª ed. Philadelphia: Elsevier; 2016.\n\n\n\n386                                                                                                                                                                                                                                                                            387\n---\n                                                                                                                                                                   METABOLISMO FOSFOCÁLCICO,                                          TUMORES                          7\n                                                                                                                                                                                                 NEUROENDOCRINOS Y MEN\n\n\n\n       17     No se han descrito casos de hipoparatiroidismo como consecuencia de:                                                               COMENTARIO\n              A. La administración de 131I en la enfermedad de Graves.                                                                           La terapia con glucocorticoides es la causa más frecuente de osteoporosis secundaria.\n              B. Depósitos de cobre en la enfermedad de Wilson.                                                                                  Además de tener efectos directos en el osteoblasto y en el\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>DAWSON-HUGHES<|>PERSON<|>Dawson-Hughes is an author who has written about vitamin D deficiency in adults, including its definition, clinical manifestations, and treatment.)\n##\n(\"entity\"<|>UPTODATE<|>ORGANIZATION<|>UpToDate is a clinical decision support resource that provides evidence-based information on various medical topics, including vitamin D deficiency.)\n##\n(\"entity\"<|>WALTHAM<|>GEO<|>Waltham is a city in Massachusetts, USA, where UpToDate Inc. is located.)\n##\n(\"entity\"<|>MELMED<|>PERSON<|>Melmed is an author who has contributed to the Williams Textbook of Endocrinology, discussing various aspects of endocrinology.)\n##\n(\"entity\"<|>PHILADELPHIA<|>GEO<|>Philadelphia is a city in Pennsylvania, USA, where the Williams Textbook of Endocrinology is published.)\n##\n(\"entity\"<|>DREZNER<|>PERSON<|>Drezner is an author who has written about the causes of vitamin D deficiency and resistance.)\n##\n(\"relationship\"<|>DAWSON-HUGHES<|>UPTODATE<|>Dawson-Hughes's work on vitamin D deficiency is featured in UpToDate, a resource for medical professionals<|>8)\n##\n(\"relationship\"<|>MELMED<|>UPTODATE<|>Melmed's contributions to endocrinology are included in UpToDate's medical literature<|>7)\n##\n(\"relationship\"<|>DREZNER<|>UPTODATE<|>Drezner's research on vitamin D deficiency is also referenced in UpToDate<|>7)\n##\n(\"relationship\"<|>MELMED<|>PHILADELPHIA<|>Melmed's textbook is published in Philadelphia, linking the author to the city<|>5)\n##\n(\"relationship\"<|>DAWSON-HUGHES<|>WALTHAM<|>Dawson-Hughes's work is associated with UpToDate, which is based in Waltham<|>5)\n##\n(\"relationship\"<|>DREZNER<|>UPTODATE<|>Drezner's work on vitamin D deficiency is included in UpToDate, a resource for medical professionals<|>7)\n<|COMPLETE|>"}]}